Developing SENISCA's global network to meet future needs: grant applications, oligonucleotide synthesis, and pharmaceutical partners
Innovate UK
Senisca Ltd
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cell aging. This innovation works by restoring the ability of cells to 'fine tune' the expression of their genes to rejuvenate aged cells.    At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.    Because oligonucleotide therapeutics is one of the fastest-growing therapeutic sectors globally, cutting edge cell delivery technologies are in constant and fast-moving development. To stay abreast of these developments, SENISCA needs to dedicate a strong internal team to the task of securing world leading partnerships for oligonucleotide synthesis and cell delivery in-licensing. This will be a key success factor in our ability to reach Phase 1 to Phase 3 clinical-testing stage for our drug pipeline, and ensure that SENISCA becomes a leading Oligonucleotide therapeutics company globally. The success of these partnerships will also provide a solid foundation to bid for collaborative EU-based grant opportunities and open the door to future co-development pharmaceutical partnerships.    We will be assigning research tasks to members of the SENISCA team, sub-contracting research to a drug development market specialist, and sourcing a pharmaceutical partnering agency to assist us with our partner search. We also aim to attend at least one networking event/conference in early 2022 (either online or in person) to increase our international network and visibility.    This project will lead to innovation within the senescence field. SENISCA is proposing effective treatments (and potentially cures) for age-related diseases such as Idiopathic Pulmonary Fibrosis (IPF), Osteoarthritis (OA) and Age-related Macular Degeneration (AMD). These diseases currently have limited treatment and no cure. By starting the search for global partners, we will allow for the exchange of scientific knowledge and expertise, and we will accelerate SENISCA's R&D and route towards commercialisation.
Missing/Incomplete